Quinapril Hydrochloride
FDA-approved product (tablet, oral), marketed as Accupril, Quinapril Hydrochloride.
- Registered studies
- 33
- Lab records
- 0
- Pathogens at ≥40%
- 1 of 4
Chemical structure
Existing / approved use
Documented · FDA, WHO, ChEMBLApproved for
- Cardiovascular disease
- Diabetes mellitus
- Heart failure
- Hypertension
- Kidney failure
- Stroke
Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗
- WHO therapeutic group
- Ace inhibitors, plain
- Anti-infective classification
- Not classified as an anti-infective.
Repurposing investigation
This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for this infection.
AI-predicted activity
AI prediction · nothing measured- MRSA35.8% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
- E. coli33.7% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
- K. pneumoniae15.5% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
- M. tuberculosis62.3% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.
Evidence
Clinical and experimental
Documented evidenceClinical
33registered studies name this medicine, for any condition. See them below.
Experimental
No evidence found
No laboratory measurement against the four pathogens in the ChEMBL records loaded here.
Docking
Computational · nothing measuredDihydrofolate reductase ↗ (E. coli)
Not yet docked: queued in the docking rundetails
KPC-2 carbapenemase ↗ (K. pneumoniae)
Not yet docked: queued in the docking rundetails
Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)
Not yet docked: queued in the docking rundetails
Dihydrofolate reductase ↗ (MRSA)
Not yet docked: queued in the docking rundetails
AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.
Other medicines to investigate
AI prediction · nothing measuredOther repurposing candidates: approved medicines besides Quinapril Hydrochloride with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.
Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.
- PlecanatideExisting use: Constipation52.2% AI-predicted activityagainst K. pneumoniae15 registered studies
- SotorasibExisting use: Neoplasm, Non-small cell lung carcinoma51.3% AI-predicted activityagainst K. pneumoniae50+ registered studies
- Lanreotide AcetateExisting use: Acromegaly, Carcinoid syndrome50.5% AI-predicted activityagainst K. pneumoniae50+ registered studies
- Terlipressin AcetateExisting use: Hepatorenal syndrome, Kidney failure, Renal insufficiency49.5% AI-predicted activityagainst K. pneumoniae7 registered studies
- LetermovirExisting use: Cytomegalovirus infection, Infection, Viral disease49.0% AI-predicted activityagainst K. pneumoniae50+ registered studies
- Codeine SulfateExisting use: Cough, Drug dependence, Migraine disorder and 2 more48.8% AI-predicted activityagainst K. pneumoniae23 registered studies
- Bromocriptine MesylateExisting use: Acromegaly, Adenoma, Hyperprolactinemia and 4 more48.5% AI-predicted activityagainst K. pneumoniae50+ registered studies
- PimecrolimusExisting use: Atopic eczema, Eczematoid dermatitis48.3% AI-predicted activityagainst K. pneumoniae50+ registered studies
- LypressinExisting use: Vasopressin and analogues48.2% AI-predicted activityagainst K. pneumoniae50+ registered studies
- Degarelix AcetateExisting use: Prostate adenocarcinoma, Prostate cancer, Prostate carcinoma48.2% AI-predicted activityagainst K. pneumoniae50+ registered studies
- OlaparibExisting use: Breast cancer, Breast carcinoma, Breast neoplasm and 9 more48.1% AI-predicted activityagainst K. pneumoniae50+ registered studies
- Dolutegravir SodiumExisting use: HIV infection, HIV-1 infection47.9% AI-predicted activityagainst K. pneumoniae50+ registered studies
Registered studies
A registration describes a study; it does not establish a positive result.
Rapid and Simultaneous Initiation of Four Guideline-Directed CKD Therapies (RAPID-CKD)
NCT07547878 · start 2026-04-30
Registered record
- Registry ID
- NCT07547878
- Conditions
- Chronic Kidney Disease; Type 2 Diabetes
- Interventions
- Finerenone; Semaglutide; Lotensin; Capoten; Enalapril; Monopril; Lisinopril; Univasc; Aceon; Accupril; Altace; Mavik; Edarbi; Atacand; Avapro; Cozaar; Benicar; Micardis; Diovan; Invokana; Farxiga; Jardiance; Ertugliflozin; Brenzavvy; Sotagliflozin
- Study type
- INTERVENTIONAL
- Phase
- Phase 4
- Registry status
- Not yet recruiting
- Start
- 2026-04-30
- Completion
- 2029-03-31
- Enrolment
- 64
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionChronic Kidney Disease; Type 2 DiabetesInterventionFinerenone; Semaglutide; Lotensin; Capoten +21 morePhasePhase 4Registry statusNot yet recruitingAssociation of Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers With Post-Stroke Pneumonia: A Real-World Retrospective Cohort Study
NCT07262710 · start 2025-12-01
Registered record
- Registry ID
- NCT07262710
- Conditions
- Post-stroke Pneumonia
- Interventions
- angiotensin converting enzyme inhibitors; Calcium Channel Blockers; Angiotensin Receptor Blockers
- Study type
- OBSERVATIONAL
- Phase
- Not recorded
- Registry status
- Not yet recruiting
- Start
- 2025-12-01
- Completion
- 2026-08-19
- Enrolment
- 13,656
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionPost-stroke PneumoniaInterventionangiotensin converting enzyme inhibitors; Calcium Channel Blockers; Angiotensin Receptor BlockersPhaseNot recordedRegistry statusNot yet recruitingImpact of Antihypertensive Therapy on Recurrence Risk of Ovarian Cancer for Bevacizumab-associated Hypertension
NCT06515678 · start 2024-05-20
Registered record
- Registry ID
- NCT06515678
- Conditions
- Ovarian Cancer; Antiangiogenic-Associated Hypertension; Adjuvant Bevacizumab; Hypertension
- Interventions
- arm A - angiotensin converting enzyme inhibitors (ACEi); arm B - calcium channel blockers (CCBs); arm R - angiotensin receptor blockers ARB
- Study type
- OBSERVATIONAL
- Phase
- Not recorded
- Registry status
- Unknown
- Start
- 2024-05-20
- Completion
- 2024-08-31
- Enrolment
- 9,464
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionOvarian Cancer; Antiangiogenic-Associated Hypertension; Adjuvant Bevacizumab; HypertensionInterventionarm A - angiotensin converting enzyme inhibitors (ACEi); arm B - calcium channel blockers (CCBs); arm R - angiotensin receptor blockers ARBPhaseNot recordedRegistry statusUnknownEffect of Sacubitril/Valsartan on Cardiac Function in Hypertensive Patients Stratified by BMI: A Real World Study
NCT05498675 · start 2021-09-01
Registered record
- Registry ID
- NCT05498675
- Conditions
- Sacubitril/Valsartan; Hypertension; Obesity
- Interventions
- Sacubitril / Valsartan Oral Tablet [Entresto]; ACEI/ARB
- Study type
- OBSERVATIONAL
- Phase
- Not recorded
- Registry status
- Recruiting
- Start
- 2021-09-01
- Completion
- 2027-06-30
- Enrolment
- 180
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionSacubitril/Valsartan; Hypertension; ObesityInterventionSacubitril / Valsartan Oral Tablet [Entresto]; ACEI/ARBPhaseNot recordedRegistry statusRecruitingCoronavirus (COVID-19) ACEi/ARB Investigation
NCT04330300 · start 2020-04-30
Registered record
- Registry ID
- NCT04330300
- Conditions
- Hypertension; COVID-19
- Interventions
- Thiazide or Thiazide-like diuretics; Calcium Channel Blockers; ACE inhibitor; Angiotensin receptor blocker
- Study type
- INTERVENTIONAL
- Phase
- Phase 4
- Registry status
- Suspended
- Start
- 2020-04-30
- Completion
- 2021-12-01
- Enrolment
- 2,414
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionHypertension; COVID-19InterventionThiazide or Thiazide-like diuretics; Calcium Channel Blockers; ACE inhibitor; Angiotensin receptor blockerPhasePhase 4Registry statusSuspendedACEI or ARB and COVID-19 Severity and Mortality in US Veterans
NCT04467931 · start 2020-01-19
Registered record
- Registry ID
- NCT04467931
- Conditions
- Hypertension; COVID
- Interventions
- ACEI/ARB; Non-ACEI/ARB; ACEI; ARB
- Study type
- OBSERVATIONAL
- Phase
- Not recorded
- Registry status
- Completed
- Start
- 2020-01-19
- Completion
- 2020-12-31
- Enrolment
- 22,213
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionHypertension; COVIDInterventionACEI/ARB; Non-ACEI/ARB; ACEI; ARBPhaseNot recordedRegistry statusCompletedDiabetic Autonomic Neuropathy and Left Ventricular Function
NCT05713396 · start 2017-01-01
Registered record
- Registry ID
- NCT05713396
- Conditions
- Diabetes Mellitus
- Interventions
- Quinapril; Losartan; Quinapril + Losartan
- Study type
- INTERVENTIONAL
- Phase
- Phase 4
- Registry status
- Completed
- Start
- 2017-01-01
- Completion
- 2022-06-01
- Enrolment
- 59
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionDiabetes MellitusInterventionQuinapril; Losartan; Quinapril + LosartanPhasePhase 4Registry statusCompletedNT-proBNP Selected Prevention of Cardiac Events in Diabetic Patients
NCT02817360 · start 2016-02
Registered record
- Registry ID
- NCT02817360
- Conditions
- Heart Diseases; Diabetes Mellitus, Type 2
- Interventions
- RAS-antagonist and beta-blocker up-to maximal dosages; RAS-antagonist and beta-blocker none or at stable dose
- Study type
- INTERVENTIONAL
- Phase
- Phase 4
- Registry status
- Recruiting
- Start
- 2016-02
- Completion
- 2026-12
- Enrolment
- 2,400
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionHeart Diseases; Diabetes Mellitus, Type 2InterventionRAS-antagonist and beta-blocker up-to maximal dosages; RAS-antagonist and beta-blocker none or at stable dosePhasePhase 4Registry statusRecruitingChronic Angiotensin Converting Enzyme Inhibitors in Intermediate Risk Surgery
NCT01669434 · start 2015-06-01
Registered record
- Registry ID
- NCT01669434
- Conditions
- Hypotension on Induction
- Interventions
- ACEI continuation; ACEI omission
- Study type
- INTERVENTIONAL
- Phase
- Phase 4
- Registry status
- Completed
- Start
- 2015-06-01
- Completion
- 2016-12-01
- Enrolment
- 291
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionHypotension on InductionInterventionACEI continuation; ACEI omissionPhasePhase 4Registry statusCompletedACE-Inhibitor Effects on Total Hip and Knee Arthroplasty Patients
NCT01867047 · start 2013-06
Registered record
- Registry ID
- NCT01867047
- Conditions
- Adverse Effects of Angiotensin-converting-enzyme Inhibitors; Hypotension
- Interventions
- ACE-I Cessation group; ACE-I Continuation group
- Study type
- INTERVENTIONAL
- Phase
- Not applicable
- Registry status
- Terminated
- Start
- 2013-06
- Completion
- 2016-06-24
- Enrolment
- 59
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionAdverse Effects of Angiotensin-converting-enzyme Inhibitors; HypotensionInterventionACE-I Cessation group; ACE-I Continuation groupPhaseNot applicableRegistry statusTerminatedIs There an Adverse Drug Reaction Between Renin-Angiotensin System Blockade and Inhaled Anesthetics
NCT01715584 · start 2012-07
Registered record
- Registry ID
- NCT01715584
- Conditions
- Hypertension
- Interventions
- Sevoflurane/oxygen/air/nitrous oxide
- Study type
- INTERVENTIONAL
- Phase
- Phase 4
- Registry status
- Unknown
- Start
- 2012-07
- Completion
- 2019-12-31
- Enrolment
- 80
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionHypertensionInterventionSevoflurane/oxygen/air/nitrous oxidePhasePhase 4Registry statusUnknownAtrial Substrate Modification With Aggressive Blood Pressure Lowering to Prevent AF
NCT00438113 · start 2009-12
Registered record
- Registry ID
- NCT00438113
- Conditions
- Atrial Fibrillation
- Interventions
- Aggressive Blood Pressure control
- Study type
- INTERVENTIONAL
- Phase
- Phase 4
- Registry status
- Completed
- Start
- 2009-12
- Completion
- 2016-09
- Enrolment
- 184
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionAtrial FibrillationInterventionAggressive Blood Pressure controlPhasePhase 4Registry statusCompletedA Non Interventional Study To Asses The Safety, Effectiveness And Tolerability Of Quinapril (Acupil®) In An Indian Population
NCT00930722 · start 2009-06
Registered record
- Registry ID
- NCT00930722
- Conditions
- Hypertension
- Interventions
- quinapril
- Study type
- OBSERVATIONAL
- Phase
- Not recorded
- Registry status
- Completed
- Start
- 2009-06
- Completion
- 2010-06
- Enrolment
- 329
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionHypertensionInterventionquinaprilPhaseNot recordedRegistry statusCompletedAdolescent Type 1 Diabetes Cardio-Renal Intervention Trial
NCT01581476 · start 2009-01
Registered record
- Registry ID
- NCT01581476
- Conditions
- Type 1 Diabetes
- Interventions
- Statin; ACE inhibitor; Placebo; Combination therapy
- Study type
- INTERVENTIONAL
- Phase
- Phase 3
- Registry status
- Completed
- Start
- 2009-01
- Completion
- 2017-06
- Enrolment
- 443
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionType 1 DiabetesInterventionStatin; ACE inhibitor; Placebo; Combination therapyPhasePhase 3Registry statusCompletedPrognostic Value of the Circadian Pattern of Ambulatory Blood Pressure for Multiple Risk Assessment
NCT00741585 · start 2008-09-01
Registered record
- Registry ID
- NCT00741585
- Conditions
- Essential Hypertension; Cardiovascular Disease; Stroke; Chronic Kidney Disease
- Interventions
- Any antihypertensive medication alone or in combination; Any antihypertensive medication alone or in combination; Ambulatory blood pressure monitoring
- Study type
- INTERVENTIONAL
- Phase
- Phase 4
- Registry status
- Completed
- Start
- 2008-09-01
- Completion
- 2018-06-30
- Enrolment
- 21,983
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionEssential Hypertension; Cardiovascular Disease; Stroke; Chronic Kidney DiseaseInterventionAny antihypertensive medication alone or in combination; Any antihypertensive medication alone or in combination; Ambulatory blood pressure monitoringPhasePhase 4Registry statusCompleted